Head-To-Head Contrast: Amgen (AMGN) & Its Rivals

Amgen (NASDAQ:AMGN – Get Free Report) is one of 842 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare Amgen to similar businesses based on the strength of its risk, earnings, analyst recommendations, profitability, valuation, dividends and institutional ownership.

Dividends

Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 2.3%. Amgen pays out 58.5% of its earnings in the form of a dividend. As a group, “Biotechnology” companies pay a dividend yield of 1.4% and pay out 48.8% of their earnings in the form of a dividend. Amgen has raised its dividend for 14 consecutive years.

Institutional & Insider Ownership

76.5% of Amgen shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 0.9% of Amgen shares are owned by company insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Amgen and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Amgen 24.14% 114.99% 13.47%
Amgen Competitors -12,519.20% -215.47% -31.42%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Amgen and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amgen 3 18 11 1 2.30
Amgen Competitors 9959 15361 45766 1602 2.54

Amgen presently has a consensus target price of $428.62, suggesting a potential downside of 1.58%. As a group, “Biotechnology” companies have a potential upside of 118.45%. Given Amgen’s rivals stronger consensus rating and higher possible upside, analysts plainly believe Amgen has less favorable growth aspects than its rivals.

Earnings and Valuation

This table compares Amgen and its rivals gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Amgen $36.75 billion $7.71 billion 25.26
Amgen Competitors $713.93 million $9.18 million -17.98

Amgen has higher revenue and earnings than its rivals. Amgen is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Risk & Volatility

Amgen has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500. Comparatively, Amgen’s rivals have a beta of -1.85, indicating that their average stock price is 285% less volatile than the S&P 500.

Summary

Amgen beats its rivals on 10 of the 15 factors compared.

Amgen Company Profile

(Get Free Report)

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.